Sleep Trial to Prevent Alzheimer's Disease
NCT04629547
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Sleep
- Alzheimer Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Minnesota
- Last updated on ClinicalTrials.gov
- July 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.